GlassScriptPhysician profile
Sung Whang
NPI 1982800900
$4,620.68
in general payments reported to CMS, 2019-2025
15 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $153 · 2021: $400 · 2022: $1,132 · 2023: $887 · 2024: $1,215 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,469.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,759.59 | 2019-2024 | Xarelto |
| Abbvie INC. | $694.57 | 2022-2025 | Qulipta, Ubrelvy, Teflaro |
| Ucb, INC. | $399.81 | 2023-2024 | Nayzilam, Rystiggo, Briviact |
| E.R. Squibb & Sons, L.L.C. | $371.19 | 2019-2025 | Eliquis |
| Mylan Specialty L.P. | $279.87 | 2020-2023 | Yupelri |
| Alkermes, INC. | $274.16 | 2022-2024 | Aristada, Aristada Initio, Lybalvi |
| Pfizer INC. | $237.37 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.06 | 2022-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $137.65 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Neurelis, INC. | $103.13 | 2023 | Valtoco |
| Vertex Pharmaceuticals Incorporated | $89.77 | 2025 | |
| Chiesi USA, INC. | $39.56 | 2019-2025 | Kengreal, Cleviprex |
| Smith+Nephew, INC. | $22.85 | 2025 | Collagenase Santyl |
| Cumberland Pharmaceuticals, INC. | $17.56 | 2025 | Caldolor |
| Melinta Therapeutics, LLC | $15.54 | 2024 | Kimyrsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sung Whang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.